

(19)



(11)

EP 2 521 566 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
03.09.2014 Bulletin 2014/36

(51) Int Cl.:
A61K 38/36 (2006.01) A61P 7/04 (2006.01)

(21) Application number: **11700052.1**

(86) International application number:
PCT/EP2011/050191

(22) Date of filing: **07.01.2011**

(87) International publication number:
WO 2011/083153 (14.07.2011 Gazette 2011/28)

(54) **Fibrinogen preparations enriched in fibrinogen with an extended alpha chain**

Fibrinogenpräparate, die mit Fibrinogen mit einer verlängerten Alphakette angereichert sind
 Préparations de fibrinogène enrichies en fibrinogène doté d'une chaîne alpha étendue

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **08.01.2010 EP 10150391**

(43) Date of publication of application:
14.11.2012 Bulletin 2012/46

(73) Proprietor: **ProFibrix BV**
2333 CR Leiden (NL)

(72) Inventors:
 • **GRIMBERGEN, Joseph**
NL-2162 LJ Lisse (NL)
 • **KOOPMAN, Jacob**
NL-2351 CA Leiderdorp (NL)
 • **BOUT, Abraham**
NL-2751 XL Moerkapelle (NL)

(74) Representative: **Ringeling, Patricia Louise**
Enelex Innovation BV
Van der Lelijstraat 8
2614 EM Delft (NL)

(56) References cited:
WO-A1-96/41170 WO-A1-03/087160

- **MOESSON M W ET AL:** "The ultrastructure of fibrinogen-420 and the fibrin-420 clot", **BIOPHYSICAL CHEMISTRY, NORTH-HOLLAND, AMSTERDAM, NL LNKD- DOI:10.1016/J.BPC. 2004.07.021, vol. 112, no. 2-3, 20 December 2004 (2004-12-20), pages 209-214, XP004664482, ISSN: 0301-4622 cited in the application**
- **GRIENINGER G ET AL:** "Fib420, the novel fibrinogen subclass: Newborn levels are higher than adult", **BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 90, no. 7, 1 January 1997 (1997-01-01), pages 2609-2614, XP002301667, ISSN: 0006-4971**
- **TANG HUADONG ET AL:** "Alpha(E)C, the C-terminal extension of fibrinogen, has chaperone-like activity.", **12 May 2009 (2009-05-12), BIOCHEMISTRY 12 MAY 2009 LNKD- PUBMED: 19284787, VOL. 48, NR. 18, PAGE(S) 3967 - 3976, XP002582371, ISSN: 1520-4995 page 3969, column 1 page 3973, column 1 - page 3974, column 2**
- **APPLEGATE D ET AL:** "THE ALPHAEC DOMAIN OF HUMAN FIBRINOGEN-420 IS A STABLE AND EARLY PLASMIN CLEAVAGE PRODUCT", **BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 95, no. 7, 1 April 2000 (2000-04-01), pages 2297-2303, XP001021399, ISSN: 0006-4971**

EP 2 521 566 B1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).